A MP-activated protein kinase (AMPK) regulates energy generating metabolic and biosynthetic pathways during physiologic and pathologic cellular stress. AMPK activation stimulates fatty acid oxidation, 1 promotes glucose transport, 2, 3 accelerates glycolysis, 4 and inhibits triglyceride 5 and protein synthesis. 6 By increasing ATP synthesis and decreasing ATP utilization, AMPK functions to maintain normal cellular energy stores during ischemia. Chronic activation of AMPK also phosphorylates transcription factors altering gene expression 7 and modulates muscle mitochondrial biogenesis. 8 AMPK is a heterotrimer consisting of an ␣ catalytic subunit and ␤ and ␥ regulatory subunits. The primary mechanism responsible for AMPK activation involves phosphorylation of the Thr 172 residue located within the activation loop of the ␣ catalytic subunit. 9 Additional phosphorylation sites have been identified on the ␣ and ␤ subunits, but their functional roles remain uncertain. 10, 11 Activation of AMPK during myocardial ischemia, 1, 12 exercise, 13 hypoglycemia, 14 and hypoxia 15 is associated with ATP breakdown and increases in intracellular AMP. However, AMPK is also phosphorylated through AMP-independent pathways during osmotic stress 16 and metformin 17 or leptin 18 stimulation.
Activation of AMPK is very sensitive to an increase in the intracellular concentration of AMP, which promotes its allosteric activation and phosphorylation. 19, 20 Phosphorylation of the ␣ subunit Thr 172 -activating site is mediated by one or more upstream kinases, termed AMPK-activating protein kinases or AMPKK(s). 21 AMP increases liver AMPKK(s) activity through binding to the AMPK ␥ subunit, which renders AMPK a better substrate for AMPKK, and by direct activation of AMPKK by AMP. 22 However, recent findings challenge the notion that AMP has a direct effect on AMPKK 23 and have also raised the possibility that AMPKK is constitutively active. 24 The physiological mechanisms responsible for the regulation of AMPKK in the heart remain uncertain. The aims of this study were to assess whether AMPKK is activated by ischemic stress and the extent to which AMP and ATP modulate heart AMPKK action. The results indicate that heart AMPKK is activated by ischemia, but that it is not directly affected by either increases in AMP or decreases in ATP concentration. Instead, AMP augments and ATP inhibits the action of AMPKK to phosphorylate and activate the AMPK ␣ subunit by interacting with the heterotrimeric AMPK complex.
Materials and Methods
Male Sprague-Dawley rats (250 to 350 grams; Charles River Laboratories, Inc, Wilmington, Mass) were given standard chow and water before experiments. All procedures were approved by the Yale University Animal Care and Use Committee.
In Vitro Low-Flow Ischemia
Rats were anesthetized with pentobarbital sodium (60 mg/kg intraperitoneal) and heparinized (300 U intraperitoneal). Hearts were excised and anterogradely perfused in the working mode with Krebs-Henseleit buffer containing 1% bovine serum albumin, 0.4 mmol/L oleate, and 5 mmol/L glucose, and equilibrated with 95% O 2 /5% CO 2 at 37°C. 25 Control hearts were perfused at a preload of 15 cm H 2 O and an afterload of 100 cm H 2 O for 40 minutes. Ischemic hearts were perfused normally for 20 minutes and then flow was reduced to 15% of control (by decreasing afterload pressure to 30 cm H 2 O) for 1 to 20 minutes. Hearts were freeze-clamped in liquid nitrogen and stored at Ϫ80°C.
In Vivo Regional Ischemia
Anesthetized rats were endotracheally intubated and ventilated with a small animal respirator, and they underwent thoracotomy to ligate the proximal left coronary artery for 10 minutes. Control rats underwent sham thoracotomy. Hearts were then rapidly excised and freeze-clamped in liquid nitrogen.
In Vivo AICAR Infusion
The AMPK-activator 5-amino-4-imidazolecarboxamide (AICAR) (Sigma, St. Louis, Mo), which is converted to the monophosphorylated metabolite ZMP that is an AMP mimetic, was administered intravenously (100 mg/kg bolus and 10 mg/kg per minute infusion for 60 minutes) to chronically catheterized rats. 3 Control rats received saline infusions. Plasma glucose was maintained constant with a variable infusion of 20% dextrose to prevent hypoglycemia, as previously described. 3 At the end of the infusion, rats were anesthetized with intravenous pentobarbital (50 mg/kg), and the hearts were rapidly excised and freeze-clamped in liquid nitrogen.
Tissue Fractionation
Heart tissue was homogenized in buffer containing 125 mmol/L Tris, 1 mmol/L EDTA, 1 mmol/L EGTA, 250 mmol/L mannitol, 50 mmol/L NaF, 5 mmol/L NaPPi, 1 mmol/L DTT, 1 mmol/L benzamedine, 0.004% trypsin inhibitor, and 3 mmol/L NaN 3 (pH 7.5). 13 After centrifugation at 14 000g for 20 minutes, the supernatant was fractionated by the sequential addition of polyethyleneglycol (PEG) into 2.5% to 6% and 6% to 10% precipitants and Ͼ10% supernatant. Fractions were resuspended in homogenizaiton buffer without mannitol. Protein concentrations were determined using the Bradford assay (BioRad reagent).
Immunoblotting
Proteins were diluted in Laemmli sample buffer before SDS-PAGE. 13 After transfer to polyvinylidine difluoride membranes, proteins were immunoblotted with pan-␣ (␣ 1 /␣ 2 ) AMPK antibody at 1:10 000 dilution (kind gift from Dr M. Birnbaum) and anti-pThr 172 AMPK antibody at 1:5000 dilution (Cell Signaling, Beverly, Mass). Proteins were detected with enhanced chemiluminescence and autoradiographs were quantified using densitometry.
AMPKK Assay
Heart AMPKK activity was assessed by measuring the AMPKKinduced Thr 172 phosphorylation of rAMPK substrates in vitro. Initial experiments demonstrated that AMPKK activity was present almost exclusively in the 6% to 10% PEG fraction (see Results). To assess AMPKK activity, protein (10 g) from the 6% to 10% PEG fraction was incubated with 10 pmol of truncated ␣ 1 1-312 fusion protein (N-terminal maltose binding protein), 24 or 5 pmol of ␣ 1 ␤ 1 ␥ 1 rAMPK containing an R70Q mutation in the ␥ 1 AMP-binding site, wild-type 26 Incubations were performed in 25 L of AMPKK assay buffer (20 mmol/L Tris, 5 mmol/L MgCl 2 , 0.2 mmol/L ATP, 0.5 mmol/L DTT, 0.1% Tween, 1 mg/mL bovine serum albumin; pH 7.5). In experiments designed to assess the effects of nucleotides on AMPKK activity, AMP (0 to 200 mol/L), ATP (400 mol/L to 10 mmol/L), and ZMP (0 to 1000 mol/L; Sigma, St. Louis, Mo) were added to the incubation mixture. Samples were diluted with Laemmli buffer, subjected to SDS-PAGE, and immunoblotted with anti-pThr 172 AMPK and pan-␣ AMPK antibodies.
AMPK Activity Assay
Endogenous heart AMPK activity, as well as the catalytic activity of rAMPK incubated with AMPKK, were assessed with a kinase assay measuring the incorporation of [␥-
32 P]-ATP into the SAMS peptide. 13 Endogenous AMPK activity was measured using 10 g of 2.5% to 6% PEG fraction protein prepared from heart homogenates. The activity of ␣ 1 1-312 fusion protein or heterotrimeric rAMPK used as AMPKK substrates was measured after isolation with a Ni-NTA kit (Qiagen, Valencia, Calif), which bound the epitope-tagged recombinant proteins via their polyhistidine sequences.
Statistics
Results were analyzed using Student t test and are presented as meansϮSEM. Results were significant at PϽ0.05.
Results

AMPK and AMPKK Fractions
We initially evaluated whether AMPK and AMPKK might be separately enriched using PEG precipitation of heart homogenates. Immunoblots demonstrated that endogenous AMPK was present predominantly in the 2.5% to 6% PEG fraction ( Figure 1A ), whereas AMPKK activity was almost exclusively in the 6% to 10% fraction ( Figure 1B ). Conditions for optimizing the AMPKK assay were then established. AMPKK activity was found to be linear for 20 minutes ( Figure 1C ), using up to 25 g of 6% to 10% PEGprecipitated protein from ischemic hearts ( Figure 1D ), so that AMPKK assays were subsequently performed with 10 g protein for 10 minutes.
AMPK and AMPKK Activity During In Vitro Ischemia
We next assessed whether ischemia activated AMPK and AMPKK activity in perfused working rat hearts. Endogenous AMPK Thr 172 phosphorylation ( Figure 2A ) and activity (Figure 2B) increased 2-to 3-fold (PϽ0.01) after low-flow ischemia. Incubation of the AMPKK fraction with heterotrimeric ␣ 1 ␤ 1 ␥ 1 rAMPK as substrate demonstrated a 4-to 5-fold (PϽ0.01) increase in AMPKK activity in ischemic hearts ( Figure 2C ). The increase in ischemic heart AMPKK activity was very rapid, increasing 3-fold after 1 minute and reaching maximal activity by 5 to 20 minutes. The accumulation of phosphorylated AMPK was less rapid (PϽ0.05), but also significant, during the first 2 minutes of ischemia, and was maximal after 5 to 20 minutes. Because AMPK was not present in the AMPKK fraction, there was no detectable endogenous phosphorylated Thr 172 AMPK in the incubations.
Effects of In Vivo Ischemia on AMPK and AMPKK Activity
To determine whether AMPKK was also activated by regional ischemia in the intact rat in vivo, we measured AMPK and AMPKK activity after coronary occlusion. Regional ischemia stimulated endogenous AMPK phosphorylation ( Figure 3A ) and increased AMPK activity 3-fold (PϽ0.01) ( Figure 3B ). Regional ischemia also stimulated AMPKK activity: phosphorylation of ␣ 1 ␤ 1 ␥ 1 rAMPK increased significantly (PϽ0.05) ( Figure  3D ), and the phosphorylation of the ␣ 1 1-312 also tended to be greater after in vivo ischemia ( Figure 3C ).
Effects of AMP on Heart AMPKK Activity In Vitro
To determine whether heart AMPKK is activated directly by AMP, perfused heart AMPKK was incubated with varying concentrations of AMP and either the ␣ 1 1-312 fusion protein or ␣ 1 ␤ 1 ␥ 1 rAMPK containing an R70Q mutation in the ␥ 1 AMP binding site. These substrates enabled assessment of the direct effects of AMP on AMPKK, without the potentially confounding effect of AMP interacting with the heterotrimeric complex to render the substrates more effective targets for AMPKK. With the addition of physiologic concentrations of AMP (10 to 200 mol/L) found in the ischemic heart, 20, 27 there was no augmentation of AMPKK-stimulated Thr Enrichment of AMPK and AMPK kinase (AMPKK) activity in heart homogenate fractions. A, Ischemic heart homogenates were fractionated using PEG precipitation and immunoblotted with pan-␣ AMPK antibody (*PϽ0.01 vs both 6% to 10% and Ͼ10%). B, PEG fractions (25 g protein) were incubated with 10 pmol ␣ 1 1-312 fusion protein for 10 minutes. ␣ 1 1-312 was then immunoblotted with pThr 172 and pan-␣ AMPK antibodies to measure AMPKK activity (*PϽ0.01 vs both 2.5% to 6% and Ͼ10% fractions). C, AMPKK (10 g protein from 6% to 10% fraction) from ischemic hearts was incubated with 5 pmol ␣ 1 ␤ 1 ␥ 1 rAMPK (*PϽ0.01 vs 0 minutes). D, AMPKK was incubated with 5 pmol ␣ 1 ␤ 1 ␥ 1 rAMPK for 10 minutes. rAMPK was then immunoblotted with pThr 172 and pan-␣ AMPK antibodies to measure AMPKK activity (*PϽ0.01 vs 5 g AMPKK). Values are meansϮSE for 3 independent experiments.
Figure 2.
Kinetics of AMPK and AMPKK activation in the in vitro ischemic heart. AMPK and AMPKK activities were assessed in the working heart model after control or low-flow ischemic perfusions. A, Endogenous heart AMPK was immunoblotted with pThr 172 and pan-␣ AMPK antibodies. B, Endogenous AMPK activity was measured in the 2.5% to 6% PEG fraction of heart homogenates using the SAMS peptide as a substrate (*PϽ0.01 vs 1-minute control; †PϽ0.01 vs 20-minute control). C, ␣ 1 ␤ 1 ␥ 1 rAMPK (5 pmol) was incubated with heart AMPKK (10 g) for 10 minutes and then immunoblotted with pThr 172 and pan-␣ AMPK antibodies to measure AMPKK activity (*PϽ0.05 vs 1-minute control; †PϽ0.01 vs 20-minute control). Values are meansϮSE for 3 independent experiments.
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In contrast, the addition of AMP did enhance the action of heart AMPKK to phosphorylate ( Figure 5A and 5B) and increase the catalytic activity ( Figure 5C and 5D) of rAMPKs containing intact AMP-binding domains (
AMP clearly augmented the ability of ischemic heart AMPKK to activate the ␣ 1 ␤ 1 ␥ 1 and ␣ 2 ␤ 1 ␥ 1 rAMPKs ( Figure  5 ). Although AMP had little discernible effect to increase rAMPK Thr 172 phosphorylation (Figure 5Aand 5B) , it did slightly and significantly increase the ability of control heart AMPKK to stimulate rAMPK activity ( Figure 5C and 5D ). Taken together, these observations suggest that AMP interaction with rAMPKs containing functional ␥ subunits renders the ␣ subunits better substrates for Thr 172 phosphorylation, particularly by ischemic heart AMPKK.
Effects of AICAR Infusion and ZMP on Heart AMPKK Activity
To further examine the physiological importance of nucleotide interaction with the ␥ subunit in mediating AMPK phosphorylation by heart AMPKK, we assessed the mechanisms by which AICAR activates AMPK in the heart. 3 AICAR is converted to the AMP mimetic compound ZMP 28 and is known to activate heart AMPK activity in vivo. 3 AICAR infusion increased heart AMPK Thr 172 phosphorylation ( Figure 6A ) but had no effect on heart AMPKK activity, as assessed in vitro with either the ␣ 1 1-312 fusion protein or the ␣ 1 ␤ 1 ␥ 1 rAMPK ( Figure 6B and 6C ). Interestingly, ZMP had no effect to stimulate AMPKK phosphorylation of the truncated ␣ 1 1-312 fusion protein ( Figure 6B ), but it clearly increased the ability of heterotrimeric ␣ 1 ␤ 1 ␥ 1 rAMPK to be phosphorylated by AMPKK ( Figure 6C ). These results suggest that the AMP mimetic ZMP potentiates AMPKK action through interaction with the ␥ subunit, rendering AMPK a better substrate for the upstream kinase. In the absence of AMPKK activation, this physiological mechanism appears to account for AICAR-stimulated AMPK phosphorylation in the heart in vivo.
Effects of ATP on Heart AMPKK Action
ATP concentrations also decrease during ischemia; 12, 27 therefore, we examined the hypothesis that normal physiologic concentrations of ATP might inhibit AMPKK directly or inhibit the ability of AMPK to be phosphorylated by heart AMPKK. Heart AMPKK was incubated with varying ATP concentrations and either the truncated ␣ 1 1-312 fusion protein or heterotrimeric ␣ 1 ␤ 1 ␥ 1 rAMPK (Figure 7) . ATP (5 to 10 mmol/L) had no effect on AMPKK-mediated phosphorylation of the ␣ 1 1-312 fusion protein ( Figure 7A ) but did significantly inhibit the ability of AMPKK to phosphorylate ␣ 1 ␤ 1 ␥ 1 rAMPK ( Figure 7B ). These results indicate that physiologic intracellular concentrations of ATP indirectly inhibit the action of heart AMPKK through interaction with the heterotrimeric AMPK complex.
Discussion
These results elucidate the dual mechanisms regulating the phosphorylation and activation of AMPK by upstream AMP-KK(s) in the ischemic heart. First, AMPKK activity per se is increased by both low-flow ischemia in vitro and regional ischemia in vivo. Second, AMP and ATP interactions with the heterotrimeric AMPK complex reciprocally modulate its suitability as a substrate to be phosphorylated by heart AMPKK. The findings suggest that the increases in AMP and decreases in ATP concentrations that occur in the ischemic heart 12, 20, 27 have an indirect influence on AMPKK action, rather than a direct effect on AMPKK activity. In addition, the results of the AICAR/ZMP experiments further demonstrate that the interaction of nucleotides with heterotrimeric AMPK are important and sufficient to increase AMPK Thr 172 phosphorylation in vivo, even in the absence of direct heart AMPKK activation.
Both in vitro and in vivo myocardial ischemia caused significant increases in AMPKK activity in these experiments. In contrast, previous studies in noncardiac tissues and cells have observed greater AMPK phosphorylation and . AMPK and AMPKK activation in the in vivo ischemic heart. Heart AMPK and AMPKK activity after sham operation (nϭ7) or regional ischemia (nϭ6) for 10 minutes in vivo. A, Endogenous heart AMPK was immunoblotted with pThr 172 and pan-␣ AMPK antibodies. B, AMPK activity was measured in 2.5% to 6% PEG fractions using the SAMS peptide assay (*PϽ0.01 vs control). C and D, AMPKK (10 g) activity was assessed with ␣ 1 1-312 fusion protein (10 pmol) or ␣ 1 ␤ 1 ␥ 1 rAMPK (5 pmol activation in the absence of increased AMPKK activity. Hypoglycemia increased Thr 172 phosphorylation and AMPK activity without altering AMPKK activity in INS-1 cells. 24 Similarly, in situ contraction increased AMPK phosphorylation in skeletal muscle without increasing the activity of LKB1, 29 a recently identified AMPKK. 23, 30 Although these findings raised the possibility that AMPKK might be constitutively active, this does not appear to be the case in the heart during ischemic stress.
The mechanisms by which AMPKK action is increased in the ischemic heart were elucidated through the use of different substrates to measure AMPKK activity. Both the ␣ 1 1-312 fusion protein 24 and heterotrimeric rAMPKs 26 were effective substrates for the heart AMPKK assay in vitro. Measurement of AMPKK activity in the absence of AMP demonstrated intrinsic AMPKK activation in the ischemic heart. The use of rAMPK substrates without normally functional AMP-binding sites (␣ 1 1-312 fusion protein and ␣ 1 ␤ 1 ␥ 1 rAMPK R70Q mutation) in the AMPKK assays also enabled us to demonstrate that AMP has no direct effects to increase AMPKK activity. AMPK activation in the absence of measurable changes in the AMP concentration has been implicated in the response of noncardiac tissues to leptin, 18 osmotic stress, 16 and metformin, 16, 17 but AMPKK activity has not been assessed in these experiments and the specific mediators of presumed AMPKK activation in these settings remain unknown.
In contrast, when AMP was added to ischemic heart AMPKK incubated with intact heterotrimeric ␣ 1 ␤ 1 ␥ 1 or ␣ 2 ␤ 1 ␥ 1 rAMPK, we observed an increase in ␣ subunit Thr 172 phosphorylation and AMPK activity. These results, taken together with the ␣ 1 fusion protein and R70Q ␣ 1 ␤ 1 ␥ 1 rAMPK findings, are consistent with the hypothesis that AMP-binding to the ␥ subunit induces a conformational change in the heterotrimeric AMPK complex, which renders the ␣ subunit more susceptible to phosphorylation by AMPKK. 22, 31, 32 Interestingly, we found less striking effects of AMP to render AMPK a better substrate for nonischemic heart AMPKK, raising the possibility that activated AMPKK from the ischemic heart may better-recognize the change in AMPK conformation induced by AMP-binding to the ␥ subunit. Although these studies were not designed to assess protein phosphatases in the ischemic heart, it is possible that AMP binding to the ␥ subunit may also decrease the susceptibility of ␣ subunit pThr 172 to dephosphorylation by heart protein phosphatases, as previously shown in liver. 19 In the ischemic heart, inhibition of oxidative metabolism causes ATP breakdown and leads to the formation of AMP through the action of adenylate kinase. 33 Our results indicate that the decline in ATP concentration, which occurs in the ischemic heart, 12,27 may also contribute to the phosphorylation and activation of AMPK. The concentrations of ATP (5 to 10 mmol/L) present in heart under nonischemic conditions 12, 27 clearly inhibited AMPKK phosphorylation of rAMPK substrate that contained an intact ␥ subunit AMP binding site. However, these same concentrations of ATP had no discernible effect to inhibit AMPKK activity directly, as assessed using the ␣ 1 1-312 fusion protein as substrate. Thus, these findings suggest that AMP and ATP interact with the AMPK complex in a reciprocal fashion to modulate its suitability as an AMPKK substrate, rather than acting directly on AMPKK.
This study focused on AMPKK phosphorylation of the critical ␣ subunit Thr 172 -activating site. The ␣ subunits contain additional phosphorylation sites, Thr 258 and Ser
485
(␣ 1 )/Ser 491 (␣ 2 ), but they do not appear to be important determinants of AMPK catalytic activity. 32 The amino acid sequences surrounding the Thr 258 and Ser 485 residues are significantly different from those surrounding Thr, 172 suggesting that distinct upstream kinases are responsible for their phosphorylation. 32 In addition, glycogen may modulate AMPK activity through interaction with the ␤ subunit glycogen binding domain. 34 The ␤ subunit also contains several phosphorylation sites, 10, 32 including Ser 108 , which may be autophosphorylated by the ␣ subunit. 32 Whereas this study provides insight into the ischemic regulation of Thr 172 phosphorylation by AMPKK, the physiologic regulation and role of these additional AMPK phosphorylation sites in the heart remain to be determined.
AMPK is activated in the ischemic heart 1 and increases glucose transport by stimulating GLUT4 translocation to the sarcolemma 3 and activates phosphofructokinase-2, which accelerates glycolysis. 4 Recent results indicate that transgenic mice, expressing a dominant-negative AMPK catalytic subunit, have impaired ischemic 12 and postischemic glucose uptake. 12, 35 AMPK-deficient hearts demonstrate poor recovery of left ventricular function, increased necrosis, and myocyte apoptosis after low-flow ischemia and reperfusion, 12 suggesting that AMPK may have a cardioprotective role in the heart during ischemia-reperfusion. These results highlight the importance of further understanding the upstream pathways involved in AMPK activation in the ischemic heart.
Recent studies have identified the tumor suppressor LKB1 to be an upstream AMPKK in the liver. 23, 30 Although we have observed that the heart AMPKK fraction contains LKB1, LKB1 is also present in PEG fractions that have no detectable AMPKK activity (unpublished data). The latter observation may be attributable to dissociation of LKB1 from STRAD and/or MO25, two modifier proteins that form a functional complex with LKB1 and potentiate its Thr 172 phosphorylation activity. 23 Further investigation is needed to delineate the role of LKB1, STRAD ␣/␤, and MO25 ␣/␤ in modulating AMPKK activity in the heart. However, liver LKB1 does not appear to be AMP-responsive, 23 consistent with our findings that AMP did not directly increase heart AMPKK activity. Figure 6 . Effects of AICAR infusion in vivo and ZMP in vitro on heart AMPKK action. After AICAR or saline infusions in vivo, heart AMPK phosphorylation and AMPKK activity were assessed. A, Phosphorylated and total endogenous heart AMPK were immunoblotted with pThr 172 and pan-␣ AMPK antibodies, respectively. Heart AMPKK activity was measured as the phosphorylation of ␣ Although we found detectable baseline AMPKK activity and endogenous AMPK Thr 172 phosphorylation in vivo and in vitro in the heart, AMPKK is clearly not fully activated in the nonischemic heart. The effects of anesthesia or the few seconds required to excise and freeze-clamp the hearts might have contributed to the baseline AMPKK activity observed in vivo in sham-operated rats and to some extent led to underestimation of the degree of activation of AMPKK during regional ischemia. These effects together with the inherent variability of sampling in the regional model of ischemia may explain in part why the degree of activation of AMPKK in the ischemic isolated perfused hearts was greater than in the in vivo hearts.
Since the initial submission of this manuscript, Altarejos et al have presented evidence that AMPKK is activated in the ischemic heart without a measurable increase in AMP concentration or change in LKB1 activity. 36 These observations are consistent with and complement our results, further supporting the conclusion that AMPKK activation is AMPindependent in the ischemic heart and highlighting the need to identify additional AMPKK(s) in the heart and the mechanisms activating these upstream kinase(s).
In conclusion, this study demonstrates that there are dual mechanisms operative in the ischemic heart that regulate AMPKK-mediated phosphorylation and activation of AMPK. Further understanding the molecular identity of AMPKK(s) in the heart will be important as AMPK emerges as a critical signaling pathway in the ischemic heart.
